US 11312698

I'll search for authoritative details on this specific patent number, then summarize.

US Patent 11,312,698 B2 — Summary

Source note: Details below are drawn from the full patent text provided (Google Patents, fetched 2026-09-17), plus my web searches of public patent/docket aggregators. I could not directly access a live USPTO PatentCenter or CAFC docket system; the litigation/PTAB information comes from Unified Patents, DrugPatentWatch, and Docket Alarm aggregator pages. I flag uncertainties explicitly.

Bibliographic data

Abstract

"Fosnetupitant chloride hydrochloride having improved stability, characterized by the following chemical structure:" — followed by the structure of the chloride hydrochloride salt of fosnetupitant (4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium, as the Cl⁻/HCl double salt).

Technical substance

The patent describes 4-phenyl-pyridine NK₁-receptor antagonists, including the prodrug fosnetupitant (the phosphonooxymethyl quaternary ammonium derivative of netupitant). The specification states the chloride hydrochloride salt "is tremendously resistant to decoupling of the oxo-phosphonomethyl, and reversion of the active moiety to its parent state." It also describes a one-step, acid-free synthesis reacting tertiary amines with chloromethyl dialkyl phosphate esters, and explains that combining the prodrug with two equivalents of HCl (versus dibasic salts preferred in the prior art) yields the stabilized form. FIG. 1 compares salt stability (the disodium salt being the benchmark).

Plain-language overview of the independent claims

Claim language as retrieved (via DrugPatentWatch's claim listing) is quoted below. Note the stability metric is unusual: "less than 0.7% degradants via mass degradation under air and ambient conditions for a period of 80 days" — i.e., a stability-limited product definition.

• Claim 1 — The compound fosnetupitant chloride hydrochloride, having the recited chemical structure, where the compound contains less than 0.7% degradants after 80 days under air/ambient conditions. In plain terms: the specific double salt, defined by its resistance to degradation.
• Claim 3 — A pharmaceutical composition comprising one or more pharmaceutically acceptable excipients plus that fosnetupitant chloride hydrochloride (with the same degradant limitation carried through).
• Claim 5 — An injectable pharmaceutical composition comprising excipients plus that fosnetupitant chloride hydrochloride (same limitation). This maps to the commercial IV product.
• Claim 7 — The same compound in anhydrate form, again with less than 0.7% degradants over 80 days under air/ambient conditions.
• Claim 9 — A pharmaceutical composition comprising the anhydrate form plus excipients.
• Claim 11 — An injectable pharmaceutical composition comprising the anhydrate form plus excipients.

Dependent claims 2, 4, 6, 8, 10, and 12 each narrow the corresponding independent claim by specifying that the degradants "comprise netupitant" — i.e., the quantified instability is reversion (de-phosphorylation) of the prodrug back to the parent drug netupitant.

Uncertainty: The claim text for claims 3, 5, 9, and 11 as returned by the aggregator was partially truncated ("...having the following formula:" followed by a structure image). The precise wording of those composition claims should be confirmed against the USPTO PatentCenter full-text or the printed patent, which I could not retrieve directly.

Litigation / PTAB / CAFC status (as searched)

• District court: Helsinn Healthcare SA v. Gland Pharma Ltd, D.N.J. Nos. 2:22-cv-04635 and 3:22-cv-04635 (same case, two docket citations), filed 2022-07-17/18, cause 35 U.S.C. §271 infringement. One listing shows the case as closed as of 2022-12-23; another aggregator listing shows it as open. This inconsistency is unresolved in my sources.
• PTAB: IPR2025-00948, Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A. — instituted 2025-11-19, with a scheduling order issued; activity through at least January 2026 (Patent Owner exhibits 2071–2072). I could not confirm from my sources whether US 11,312,698 is the challenged patent in that IPR versus a related Helsinn patent — the docket page I retrieved did not name the patent.
• CAFC (2026): My searches returned no Federal Circuit appeal docket involving patent 11,312,698. I cannot rule out a pending or sealed appeal; I simply found no authoritative record of one.

Related family / commercial context

• Continuation/related US filings in the same family include US 8,426,450; US 8,895,586; US 9,908,907; US 10,208,073; US 10,717,721; and US 17/699,522 (published US 2022/0401463 A1; the Google Patents event log also references US 12,071,421 B2 in connection with that application).
• The patent is listed in the Orange Book for AKYNZEO (fosnetupitant chloride hydrochloride / palonosetron hydrochloride; NDA 210493, IV powder 2018 and IV solution 2020), with a listed expiration of 2032-05-23 and "DS, DP" (drug substance / drug product) patent codes per DrugPatentWatch.
• International family equivalents include EP 2785706 B1, with SPCs in the Netherlands, Denmark, and Lithuania noted.

I'll search for litigation involving US patent 11312698 specifically.

Let me dig deeper into the specific case details and check for additional cases.

Let me check for any PTAB proceedings or additional cases involving this specific patent.

Litigation involving U.S. Patent No. 11,312,698

Based on searches of Unified Patents' litigation portal (which indexes specific patents in cases), CourtListener/Free Law Project dockets, DrugPatentWatch, and the underlying court filings, I identified one litigation matter in which U.S. Patent No. 11,312,698 was pleaded. I did not find any PTAB (IPR/PGR) proceeding, ITC investigation, or other district court case naming this specific patent.

Case 1 — Helsinn Healthcare S.A. v. Gland Pharma Limited

Background on the dispute: Helsinn brought the action against Gland after receiving Paragraph IV notice letters regarding Gland's ANDA No. 217374, directed to generic EQ 11.75 mg/mL fosnetupitant chloride hydrochloride and 0.0125 mg/mL palonosetron hydrochloride, 235 mg/0.25 mg per 20 mL single-dose vials for IV administration (a generic of Helsinn's AKYNZEO IV product).

U.S. Patent No. 11,312,698 was one of ten Helsinn patents asserted in the case, alongside U.S. Patent Nos. 8,426,450; 8,895,586; 9,186,357; 9,403,772; 9,908,907; 10,208,073; 10,624,911; 10,717,721; and 10,828,297. Notably, the '698 patent (granted April 26, 2022) was the subject of Gland's Second Notice Letter, dated on or about July 11, 2022, and Gland's counterclaims included declarations of non-infringement and invalidity specifically as to the '698 patent (e.g., Eighteenth and Twentieth Counterclaims). Gland's counterclaims were dismissed with prejudice as part of the settlement, so no merits ruling on the '698 patent was issued.

Sources / grounding:

• Unified Patents litigation portal, filter "Patents in Case: 11312698": https://portal.unifiedpatents.com/litigation/caselist?patents=11312698&sort=-filed_date
• CourtListener docket, Helsinn Healthcare S.A. v. Gland Pharma Limited, 3:22-cv-04635: https://www.courtlistener.com/docket/63601016/helsinn-healthcare-sa-v-gland-pharma-limited/
• Consent Judgment and Dismissal Order (D.N.J. 22-4635): https://paragraphfour.com/wp-content/uploads/2022/07/njdc22cv4635CJ.pdf
• Gland's Amended Answer/Counterclaims (D.I. 25): https://storage.courtlistener.com/recap/gov.uscourts.njd.[499051](/patent/499051)/gov.uscourts.njd.499051.25.0.pdf
• DrugPatentWatch litigation record: https://www.drugpatentwatch.com/p/litigation/casename/index.php?query=HELSINN+HEALTHCARE+S.A.+v.+GLAND+PHARMA+LIMITED%7c3%3a22-cv-04635
• IPWatchdog Patent Filings Roundup (July 29, 2022), listing 11312698 among the asserted patents in 2:22-cv-04635: https://ipwatchdog.com/2022/07/29/patent-filings-roundup-future-waco-patent-cases-headed-wheel-ax-wireless-launches-wifi-6-campaign-helsinn-paragraph-iv-litigation/

Caveats and things I specifically did / did not find

• No PTAB proceedings on the '698 patent. DrugPatentWatch's PTAB listing for the NETUPITANT; PALONOSETRON HYDROCHLORIDE product shows IPR petitions filed May 1, 2025 by Azurity Pharmaceuticals, but those target U.S. Patent Nos. 10,828,297, 8,623,826, and 9,186,357 — not the '698 patent. Source: https://www.drugpatentwatch.com/p/litigation/drugname/index.php?query=NETUPITANT%3b+PALONOSETRON+HYDROCHLORIDE
• Other Helsinn disputes I found do not involve this patent. For example, the Delaware Cinvanti decision, the earlier ALOXI®/palonosetron cases (e.g., Helsinn v. Teva, Helsinn v. Sagent, Helsinn v. Cipla, Helsinn v. Fresenius Kabi), and the Taiwan Nan Kang / O-Klon case (which concerns Taiwan patent I342212) do not name U.S. Patent No. 11,312,698.
• Google Patents shows a "Family has litigation" flag for the US11,312,698 family (via Darts-ip), which is consistent with the Gland matter but does not by itself identify additional cases.
• I was unable to verify the docket directly on PACER within this session; my conclusions rest on the indexed third-party sources and the filings quoted above. I would recommend confirming the final docket status and the sealed judgment terms via PACER (D.N.J. 3:22-cv-04635) if you need certified detail.

Summary: The only known litigation involving U.S. Patent No. 11,312,698 is Helsinn Healthcare S.A. v. Gland Pharma Limited, D.N.J. Case No. 3:22-cv-04635 (also indexed as 2:22-cv-04635), filed July 18, 2022, and resolved by a Consent Judgment and Dismissal Order (claims dismissed with prejudice) with the case closed on December 23, 2022 and the public judgment entered January 18, 2023.

I'll verify the canonical "no proceedings" baseline against live sources before writing this up.

Now let me specifically confirm whether any AIA trial has ever targeted the '698 patent itself (including any 2026 filings).

Let me do two final confirmation searches — a 2026-filing sweep and a Slayback/other-petitioner check.

Proceedings overview

Zero (0) AIA trial proceedings have ever been filed against US 11,312,698 — no IPR, no PGR, no CBM; the canonical USPTO Open Data Portal list supplied in this prompt returns an empty set, and my independent searches (Google/Docket Alarm/Unified Patents/DrugPatentWatch, through 2026) surface no petition naming the '698 patent as the challenged patent. That means all 12 claims stand untested at the Board: claims 1–12 are neither canceled nor sustained in any AIA trial, no FWD exists, no estoppel has attached to anyone, and no PTAB proceeding is active against this patent. The defensive posture is therefore "unbroken wall, but also unhardened" — a defendant today has no free-kill claim to cite, but also faces no § 315(e)(2) estoppel and no adverse FWD findings on the record.

⚠️ Correction to the previously generated summary. That summary stated, with an express uncertainty flag, that IPR2025‑00948 (Azurity v. Helsinn) might target US 11,312,698. That is confirmed wrong. The IPR2025‑00948 record — Patent Owner's Mandatory Notices dated 2025‑05‑22, the POPR dated 2025‑09‑04, and Azurity's Director-level briefing — all identify the challenged patent as US 9,943,515 B2 ("the '515 patent"), not the '698 patent. See PTAB E2E / PTACTS petition record, IPR2025‑00948 and Docket Alarm docket, IPR2025‑00948. The prior summary's "PTAB" entry should be read as pertaining to the sibling '515 patent, not this patent.

Adjacent proceedings you must know about (NOT on the '698 patent)

These are not AIA trials on US 11,312,698 and I am not counting them as such. They are listed because they are the single most likely source of a future challenge to this patent, and because a defendant's § 315(b) window and the patent owner's discretionary-denial playbook are being built in them right now.

IPR2025‑00945 / ‑00946 / ‑00947 / ‑00948 / ‑00949 — Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A.

• Type: Inter Partes Review (five separate petitions, one per challenged patent — not a single consolidated case)
• Filed: 2025‑05‑01 (accorded filing date 2025‑05‑01)
• Patents challenged (per the consolidated caption appearing in the Peroutka deposition exhibit in IPR2025‑00947):
  • IPR2025‑00945 → US 8,623,826
  • IPR2025‑00946 → US 9,186,357
  • IPR2025‑00947 → US 9,186,357
  • IPR2025‑00948 → US 9,943,515
  • IPR2025‑00949 → US 10,828,297
  • None of these is US 11,312,698. Source: Peroutka deposition transcript exhibit, IPR2025‑00947
• Status: Instituted and in trial — Board docket shows "Decision Granting Institution of Inter Partes Review" plus a Scheduling Order, both dated 2025‑11‑19; DrugPatentWatch lists 2025‑11‑19 as the decision date for all five. Active through at least 2026‑03‑04 (Petitioner's Objections to Evidence; PO exhibits 2071–2072 filed 2026‑01‑06). See Docket Alarm docket, IPR2025‑00948
• Judge panel: not named in the public docket entries I retrieved — I do not know the APJ panel and will not guess.
• Petition grounds: § 103 obviousness of all claims 1–23 of the '515 patent, over combinations anchored on Herrstedt (triple-therapy CINV background), Herrington (single-dose aprepitant), Bös (US 6,297,375 — the netupitant genus/species reference), Campos, the EMEND label, and the ALOXI label. Azurity's expert is Dr. Stephen J. Peroutka. Azurity's conclusion: "Claims 1‑23 are unpatentable." Source: Azurity's Opposition to Helsinn's Discretionary-Denial Request, 2025‑09‑04
• Institution decision: Director referred the petitions to the merits on 2025‑09‑19, over Helsinn's discretionary-denial request; the panel then instituted on 2025‑11‑19. The Director-side reasoning, as reflected in the docket, turned on Azurity's showing of material examination error (Helsinn's alleged misrepresentation/omission of CINV data during prosecution, which Helsinn failed to squarely rebut), which under the current Office practice defeats a "settled expectations" discretionary denial. Helsinn had conceded Fintiv did not apply (no co-pending litigation) and relied on settled expectations alone.
• Final Written Decision: none has issued. Institution 2025‑11‑19 → statutory § 316(a)(11) one-year deadline puts the FWD at approximately 2026‑11‑19. That is the milestone to watch.
• Settlement / termination: none reported; the proceedings are live.
• Appeal: none — no FWD exists to appeal.
• Defensive value to you: indirect but real. If the Board cancels claims 1–23 of the '515 patent and the '297/'357/'826 patents, Helsinn's Orange Book exclusivity wall around AKYNZEO narrows materially — but the '698 patent is the drug-substance (DS) and drug-product (DP) listed patent on NDA 210493 (per DrugPatentWatch patent page for 11,312,698), and nothing in this cluster touches it. Do not let a favorable sibling-patent outcome be mistaken for a defense to the '698 patent.

Helsinn Healthcare S.A. v. Gland Pharma Limited — D.N.J. No. 3:22‑cv‑04635 (ZNQ)(LHG) (a/k/a 2:22‑cv‑04635)

This is a district court case, not an AIA trial, but it is the only assertion of the '698 patent I can find, and it is where the invalidity theories against this patent were first papered.

• Filed: 2022‑07‑18 (DrugPatentWatch lists filing 2022‑07‑17; CourtListener ECF stamp is 2022‑07‑18 — minor aggregator discrepancy)
• Asserted patents: US 8,426,450; 8,895,586; 9,186,357; 9,403,772; 9,908,907; 10,208,073; 10,624,911; 10,717,721; 10,828,297; and 11,312,698. Accused product: Gland's ANDA No. 217374, fosnetupitant chloride hydrochloride/palonosetron HCl, 235 mg/0.25 mg per 20 mL vial.
• '698-specific paragraph IV grounds (Gland's Second Notice Letter, dated 2022‑07‑11, per Gland's Twentieth Counterclaim): § 103 obviousness over WO '846; Bös; Funk; DeGoey; Krise I; and Oslob, plus § 112 indefiniteness and non-enablement directed specifically at the "less than 0.7% degradants" limitation, the "pharmaceutically acceptable excipients" limitation, and "fosnetupitant chloride hydrochloride in the form of an anhydrate." Source: Gland's Amended Answer and Counterclaims, D.N.J. 3:22‑cv‑04635, ECF 25
• Outcome: Consent Judgment and Dismissal Order signed by Judge Zahid N. Quraishi on 2023‑01‑18, entered 2023‑01‑19 (ECF 50). Gland admitted that submission of ANDA No. 217374 was "a technical act of infringement of the Helsinn Patents under 35 U.S.C. § 271(e)(2)(A)," agreed not to market until patent expiry, and — critically — "Helsinn and Gland each expressly waives any right to appeal from this Consent Judgment and Dismissal Order." No merits decision on validity or infringement was obtained. Source: CourtListener, ECF 50; consent judgment PDF. DrugPatentWatch lists the case as terminated 2022‑12‑23, i.e., settlement likely reached in December 2022 with the judgment formalized in January 2023.
• Internal inconsistency to flag: the CourtListener docket description of ECF 50 says "dismissed with prejudice," but the body text of the order (¶ 6) says "hereby dismissed without prejudice." The order text controls, but if you are relying on the dismissal's preclusive effect, pull the certified copy from PACER and verify. Gland's ¶ 4 statement — "Gland has not rebutted the statutory presumption that the Helsinn Patents are valid and enforceable" — was expressly made "without prejudice to Gland's defenses and counterclaims that the Helsinn Patents are invalid," so no issue-preclusion on validity arises from this judgment.
• Defensive value: Gland is your best source of an already-drafted invalidity case against the '698 patent, and the consent judgment did not adjudicate (or immunize) it. But note that Gland itself is very likely time-barred under § 315(b) from filing an IPR on the '698 patent: it was served with the complaint in mid‑2022, and under Click-to-Call service of a later-dismissed complaint still starts the one-year clock. If your client wants an IPR on the '698 patent and was never sued on it, Gland's prior-art theory is a free roadmap — Gland's own petition rights are probably gone.

Strategic summary

Claim status. US 11,312,698 has 12 claims (1–12), all UNTESTED in any AIA trial. Nothing is canceled. Nothing has been adjudicated patentable. The claim set covers (i) the fosnetupitant chloride hydrochloride compound per se (claim 1), (ii) the anhydrate form (claim 7), (iii) pharmaceutical compositions (claims 3, 9), and (iv) injectable compositions (claims 5, 11), each with dependent claims (2, 4, 6, 8, 10, 12) requiring that the degradants "comprise netupitant." Two independent claim families (the compound/anhydrate, and the two composition families) must each be attacked separately — a single IPR petition naming all 12 claims is the efficient approach, but only if you have art that reaches both the compound genus and the "less than 0.7% degradants over 80 days under air and ambient conditions" stability limitation. That stability limitation is the hard part: it is a product-by-property limitation with no disclosed measuring protocol beyond "mass degradation under air and ambient conditions," and Gland's § 112 indefiniteness/enablement challenge to it is the single most-filed-and-least-resolved theory against this patent.

Estoppel landscape. Because no IPR/PGR has been instituted on the '698 patent, § 315(e)(2) estoppel attaches to no one with respect to this patent. You are free to raise any § 102/§ 103 ground in district court or in a new IPR. Two cautions: (1) Azurity's estoppel will attach only as to the '826/'357/'515/'297 patents it is litigating at the Board — it does not bleed into the '698 patent, and Azurity is not your privy; (2) Gland is the party most likely barred by § 315(b), not by § 315(e)(2), and that bar is personal to Gland. If you are a new defendant facing a '698 assertion, your § 315(b) clock starts on your own service date, not on the Gland 2022 complaint. Also note that a § 315(b)-timed-out party retains the ability to join an instituted IPR under § 315(c) — but that requires an instituted IPR to exist on this patent, and there is none.

Pattern signals. The Azurity build-out is the clearest signal in the portfolio: one petitioner, five coordinated petitions, filed on a single day (2025‑05‑01), all instituted on a single day (2025‑11‑19), aimed at the efficacy/method patents ('826, '357, '515, '297) rather than at the chemistry/stability patents. That is a deliberate sequencing choice. The obvious next targets, if Azurity prevails or wants a clean 2032 wall, are the chemistry patents — 11,312,698 and its family siblings US 8,426,450, US 8,895,586, US 9,908,907, US 10,208,073, US 10,717,721, and US 12,071,421 (the continuation off Ser. No. 17/699,522). Helsinn, for its part, has not appealed anything on this family — there is no Federal Circuit appeal to chase — and it has chosen to settle rather than litigate validity (Gland 2023) and to fight discretionary denial hard at the Director level (2025 Azurity petitions, where it lost the referral). No defensive aggregator (Unified Patents, RPX, etc.) appears anywhere in the '698 chain; the Unified Patents page for US‑11312698‑B2 lists only the Gland litigation under "Related Cases."

Recommended next steps

1. If you are a defendant and Helsinn has asserted the '698 patent against you, do not wait for Azurity. There is no instituted IPR on this patent and therefore no § 315(c) join-and-ride option. File your own petition within § 315(b)'s one-year clock from service. File early — the current Director is denying institution on discretionary grounds in a large share of cases, and "settled expectations" plus material-examination-error arguments are being litigated hard on these very Helsinn patents.
2. Pull the three documents that give you the '698-specific invalidity record for free: (a) Gland's Second Notice Letter theory as recited in the Twentieth Counterclaim, D.N.J. 3:22‑cv‑04635, ECF 25, ¶¶ 125–128 (link); (b) the '698 patent's own prosecution history (App. No. 16/896,135, filed 2020‑06‑08, granted 2022‑04‑26, Examiner Douglas M. Willis) to see how the "less than 0.7% degradants" limitation was supported and whether the FIG. 1 stability data was ever reduced to a protocol; and (c) the PTO's file for US 12,071,421 B2 (the continuation off Ser. No. 17/699,522), which shares the specification and is the most likely companion target.
3. Build the § 112 case before the § 103 case. The "less than 0.7% degradants via mass degradation under air and ambient conditions for a period of 80 days" limitation defines the compound and each composition claim. Gland already teed this up as indefinite and non-enabled, as to that limitation, the excipient limitation, and the anhydrate limitation. If that limitation is indefinite, the entire claim set is exposed on a ground that is not art-dependent and not subject to any § 315(e)(2) estoppel — and, unlike a § 103 art-based ground, it cannot be mooted by a later reference.
4. Watch 2026‑11‑19. That is the approximate § 316(a)(11) FWD deadline in the five instituted Azurity IPRs. If the Board cancels claims in the '515 and '297 patents, Helsinn's remaining exclusivity on the intravenous AKYNZEO product rests disproportionately on the chemistry/stability patents — including this one — and the pressure to institute a '698 IPR will rise sharply. A final written decision from Azurity's trial on the '515 patent is the single most informative event for predicting how a '698 obviousness case would fare.
5. Verify nothing was filed in the last few weeks. The ODP feed in this prompt shows no proceedings, and my searches through 2026 surface none on the '698 patent, but AIA petitions are confidential until accorded a filing date and can appear with a lag. Before you rely on "no prior art estoppel and no prior IPR," re-run a PatentCenter "Patent Trial and Appeal Board" tab check on 11,312,698 against the live system. I am reporting an absence, and I want you to independently confirm rather than take the absence on faith.

Sources relied on: USPTO PTACTS, IPR2025‑00948 filings · Docket Alarm, IPR2025‑00948 docket · Azurity's Opposition to Discretionary Denial, 2025‑09‑04 · Helsinn POPR, IPR2025‑00948, 2025‑09‑04 · CourtListener, Helsinn v. Gland, ECF 50 · CourtListener, Helsinn v. Gland, ECF 1 (Complaint) · Gland Amended Answer / Counterclaims, ECF 25 · DrugPatentWatch patent page, 11,312,698 · DrugPatentWatch PTAB listing for the AKYNZEO drug · Unified Patents, US‑11312698‑B2

Limits on what I can tell you: no FWD, panel composition, claim-construction ruling, or settlement term exists for this patent because no AIA trial exists. I found no Federal Circuit appeal involving US 11,312,698. I could not confirm whether the "Opposition Documents" link on the Unified Patents page reflects European oppositions to EP 2785706 or something else, and I am not treating it as an AIA proceeding.

I'll research the assignment record for this patent, starting with the assignment databases and the legal events already visible on Google Patents.

Let me dig into the assignment records specifics — reel/frame, correspondent, and the original inventor assignment.

Let me try to pin down the reel/frame numbers and correspondents of record from the assignment databases and corroborating sources.

Assignment / Ownership Analysis — US Patent 11,312,698 B2

Methodological caveat up front (read this first). I could not complete a direct, live query of USPTO Patent Assignment Search (assignmentcenter.uspto.gov) or PEDS/ODP in this session — my tool access capped out mid-research. The ownership picture below is therefore reconstructed from the USPTO assignment events as mirrored in the Google Patents legal-events log for this patent (which reproduces the recorded conveyance type, assignor, assignee, and recording date), plus the patent's own front-page data and corroborating third-party sources. I could not verify reel/frame numbers, execution dates, or the recording correspondent for any entry, so I have not invented them. Where a field is unknown I say so. This is a real gap: reel/frame and correspondent are the analyst's strongest anchors, and I am flagging their absence rather than filling it with plausible-looking strings.

Inventors

Eight named inventors. Front-page addresses (from the family's issued patents) and employer at filing:

Patterns worth noting:

• Six-plus of eight inventors are Helsinn personnel (Swiss/Italian addresses clustered around the Lugano–Como–Varese–Giubiasco corridor where Helsinn operates). This is a normal captive-R&D inventor set, not a scattered or fire-sale pattern.
• The one outlier is Valentino J. Stella (University of Kansas). Stella is the named co-inventor of the underlying phosphonooxymethyl prodrug chemistry (U.S. 5,985,856, "water soluble N-phosphoryloxymethyl derivatives," assigned to the University of Kansas) — a reference the '698 patent itself cites. His presence signals a university–industry collaboration, and KU is a plausible upstream rights-holder. I found no recorded assignment of any KU interest to Helsinn in the data I could retrieve, and I cannot confirm one exists. Flagged as a diligence item, not a finding.
• No "all inventors departed within 12 months" pattern is evident. These are career Helsinn scientists; I found no evidence of a coordinated inventor exodus preceding a portfolio sale. Nothing here resembles a tech-transfer shell.

Original assignee

Helsinn Healthcare SA, Lugano/Pazzallo, Switzerland (front page: "HELSINN HEALTHCARE SA, Lugano/Pazzallo (CH)"). Original and current assignee — no change of ownership entity appears anywhere in the chain.

• Primary line of business: privately held (family-controlled) specialty pharmaceutical company focused on oncology supportive care and CINV.
• Does it ship a product embodying the claims? Yes. The '698 patent is Orange-Book-listed for AKYNZEO (fosnetupitant chloride hydrochloride / palonosetron hydrochloride, IV; NDA 210493), approved 2018-04-19 (powder, 210493-001) and 2020-05-27 (solution, 210493-002). DrugPatentWatch carries the '698 patent against AKYNZEO with DS, DP (drug substance / drug product) codes and a listed expiry of 2032-05-23.
• Status: operating. I found no Chapter 7/11, dissolution, or wind-down. The only corporate-finance event touching the patent is a group-level secured financing (below).

Assignment timeline

The Google Patents legal-events log for US 11,312,698 (mirroring USPTO assignment records) shows exactly two recorded conveyances, both post-grant and both financing-related. No inventor→Helsinn assignment appears as a distinct event on this patent's log (it may have been recorded against the parent application, or the inventors were under obligation to assign; I could not confirm either way).

• Executed date: unknown / recorded 2022-12-30 — Reel/frame: NOT RETRIEVABLE in this session

  • Conveyance: Security Interest (Security Agreement) — Google Patents caption: "SECURITY INTEREST (SEE DOCUMENT FOR DETAILS)."
  • Assignors: Helsinn Healthcare SA; Helsinn Birex Pharmaceuticals Limited; Helsinn Therapeutics (U.S.), Inc.
  • Assignee/Secured party: HAMILTON SA LLC
  • Correspondent: not retrievable (not in the mirrored event; would require the reel/frame image).
  • Context: Securitization / collateral pledge — a cross-affiliate group financing encumbering the whole Helsinn family's IP as collateral for a lender/administrative agent. Titled as an "assignment," it is expressly a security interest, not a transfer of beneficial ownership.

• Executed date: unknown / recorded 2023-09-20 — Reel/frame: NOT RETRIEVABLE in this session

  • Conveyance: Release by Secured Party
  • Assignor: HAMILTON SA LLC
  • Assignee (restored owner): Helsinn Healthcare SA; Helsinn Birex Pharmaceuticals Limited; Helsinn Therapeutics (U.S.), Inc.
  • Correspondent: not retrievable.
  • Context: Lien release — the collateral was freed when the financing was repaid/refinanced; clean title re-vested in the Helsinn entities. Google Patents renders this as "Assigned to Helsinn…," but the conveyance type is a release, not an acquisition.

Bottom line on the record: the chain begins and ends with Helsinn Healthcare SA as owner. The only intervening entries are a lender's security interest and its release — no NPE, no LLC acquisition of beneficial title, no cascading transfers.

Timeline diagram

timeline
    title Ownership of US 11312698
    2011 : Priority application filed
    2012 : Parent application filed
    2020 : CIP application filed
         : Published as US 2020 0399240 A1
    2022 : Patent granted 26 April
         : Security interest to Hamilton SA LLC
         : Helsinn sues Gland Pharma
    2023 : Release by Hamilton SA LLC

NPE / troll-pattern signals

1. Shell-entity transfer — NOT PRESENT. The only non-Helsinn name in the chain is HAMILTON SA LLC, and it entered via a Security Interest, not an assignment of title (recorded 2022-12-30). It exited by Release by Secured Party (2023-09-20). A collateral agent is not a licensing-only shell acquiring the patent; beneficial ownership never left Helsinn. No "IP/Holdings/Ventures" successor appears.

2. Known asserter in the chain — NOT PRESENT. Neither Helsinn Healthcare SA nor Hamilton SA LLC matches any published NPE list (Acacia, Marathon, IV, IPNav, Wi-LAN/Conversant, Vringo, Pendrell, Round Rock, Spangenberg entities, etc.). Helsinn is the plaintiff in the one asserted case, not an NPE holding company targeting non-competitors — it sued an ANDA filer (a generic competitor to its own marketed product).

3. Repeat correspondent across the chain — UNCLEAR / NOT VERIFIABLE. I could not retrieve the recording correspondent for either entry (no reel/frame access). The family's attorney/agent of record for prosecution is Clark Sullivan of Arnall Golden Gregory LLP (per the family's printed patents and a Helsinn PTAB filing). A single, consistent prosecution firm doing legitimate brand-pharma work is not an NPE tell, and I have no evidence of attorney recurrence across an LLC chain. Do not treat this as a signal in either direction.

4. Cascading transfers — NOT PRESENT. Two recordings, ~9 months apart, both between the same two party-sets (Helsinn group ↔ Hamilton SA LLC) and both financing-related. No chained LLCs, no shared registered-agent-address pattern, no serial re-assignment.

5. Pre-litigation transfer — NOT PRESENT. The infringement suit (Helsinn v. Gland, D.N.J. 3:22-cv-04635, filed 2022-07-18) predates the 2022-12-30 security-interest recording, so the financing was not arranged to enable assertion. And even if it had been, it ran to a lender, not to an asserting entity.

6. Bankruptcy fire-sale — NOT PRESENT. No Chapter 7/11, no §363 sale. Helsinn is operating and marketing AKYNZEO.

7. Privateering — NOT PRESENT. The '698 patent was asserted by Helsinn itself, as the operating innovator, against Gland Pharma's ANDA (ANDA No. 217374) for a generic of Helsinn's own IV product. That is direct, self-interested enforcement — the opposite of privateering.

8. Defensive aggregator — NOT PRESENT. The chain does not terminate at RPX, AST, LOT, Unified Patents, or OIN.

Verdict

Operating-company assertion.

The record — as mirrored from USPTO assignment events on the Google Patents legal-events log — shows Helsinn Healthcare SA as original and current owner, with only two lifetime recordings: a Security Interest to Hamilton SA LLC (recorded 2022-12-30) and a Release by Secured Party (recorded 2023-09-20). Both are financing mechanics, not ownership transfers; no NPE, shell LLC, or aggregator ever held title. The patent is Orange-Book-listed for AKYNZEO (NDA 210493, DS/DP, expiry 2032-05-23) and was asserted by Helsinn against an actual generic competitor (Helsinn v. Gland Pharma, D.N.J. 3:22-cv-04635, filed 2022-07-18) — squarely operating-company conduct with zero troll-pattern signals.

Verification link: USPTO Assignment Center search — https://assignmentcenter.uspto.gov/ (search by patent no. 11312698); legacy interface: https://assignment.uspto.gov/patent/index.html
(Recommend pulling the two reel/frame images directly to capture the recording correspondents I could not retrieve here.)

⚠️ Contradiction to flag against the earlier-generated sections

The previously-generated Patent summary states that IPR2025-00948 (Azurity Pharmaceuticals v. Helsinn Healthcare S.A.) was instituted 2025-11-19 and implies US 11,312,698 may be the challenged patent, while the Litigation summary states there are no PTAB proceedings on the '698 patent and that the May 2025 Azurity IPR petitions target US 10,828,297, 8,623,826, and 9,186,357 instead. These two prior sections directly conflict. My own searches did not resolve it; on the evidence I saw, the Litigation summary's position (Azurity IPRs do not name the '698 patent) appears better grounded, but this should be re-verified against PTAB before being relied upon, since a pending IPR on the '698 patent would materially affect any assertion analysis. I flag it rather than silently harmonizing it.

I'll research the specific prior-art citations for US 11,312,698. Let me search authoritative sources.

Let me get more detail on the key cited references.

Prior-Art Analysis — U.S. Patent No. 11,312,698 B2

Patent: Fosnetupitant chloride hydrochloride having improved stability
Appl. No.: 16/896,135 · Filed: 2020-06-08 · Granted: 2022-04-26 · Priority claimed: 2011-11-29 (US 61/564,537) via CIP of US 13/478,361 (2012-05-23)
Assignee: Helsinn Healthcare SA

0. Method, scope, and a critical legal caveat

Tool limitation (stated up front). I could not query USPTO PatentCenter/PAIR's full "References Cited" (front-page "U.S. PATENT DOCUMENTS" / "FOREIGN PATENT DOCUMENTS" boxes) directly; my searches returned the reference list for US 11,312,698 as indexed by PubChem/Google Patents (23 patent-art citations and 14 NPL citations). I treat that list as the authoritative citation set for this patent. Where I could not independently verify a reference's subject matter, I say so explicitly rather than guess.

Legal framework applied. Because Appl. No. 16/896,135 was filed after 2013-03-16, AIA 35 U.S.C. § 102(a)(1)/(a)(2) governs, even though the patent claims 2011 priority. Anticipation analysis therefore turns on the effective filing date of each claim:

• If a claim is supported by the 2011-11-29 provisional (61/564,537), then anything published/filed after 2011-11-29 is not § 102(a)(1) prior art to that claim.
• Most of the "Helsinn family" references listed below (US 8,426,450; WO 2013/082102; US 9,403,772; US 2017/050993 A1) were published 2013–2017 by the same inventors/assignee and share the 2011-11-29 priority. They are therefore generally excepted under § 102(b)(2)(A) (subject matter obtained from the inventor) and/or § 102(b)(2)(C) (commonly owned), and are more naturally § 102 double-patenting / § 103 references than § 102 anticipators.
• This is the single most important point for the § 102 question you asked: the references that are closest on their face (the family) are the ones least available as § 102 art, and the references that are available as § 102 art (Kansas/Stella, Roche, Krise NPL) do not disclose the claimed salt-plus-stability combination.
• As flagged in the earlier-generated sections, the exact claim text for claims 3, 5, 9, and 11 as reported by aggregators was partially truncated. I use the claim structure from that earlier section (claims 1, 3, 5, 7, 9, 11 independent; 2, 4, 6, 8, 10, 12 dependent) and flag that as an assumption.

Claim set used for the mapping (per previously generated summary):

1. Patent-document citations (23) — reference-by-reference

A. The two references the applicant expressly distinguished in the specification (highest analytical significance)

1. US 5,985,856 A — "Water soluble prodrugs of secondary and tertiary amine containing drugs and methods of making thereof"

• Assignee/inventors: University of Kansas; Stella, Krise, Zygmunt, Georg.
• Dates: Priority 1997-12-31 (Prov. 60/070,093); filed 1998-12-30; granted/published 1999-11-16.
• Description: Discloses N-phosphoryloxymethyl ("N-phosphonooxymethyl") prodrugs of secondary/tertiary amines of formulae VI/VIa/VIb, in which the quaternary ammonium center bears an external anion (A) and the phosphate bears an external cation (X). The specification exemplifies chloromethyl di-tert-butyl phosphate reacting with quinuclidine, cinnarizine, loxapine and amiodarone, and expressly contemplates the internal-salt / dual-charge forms and "any pharmaceutically acceptable cationic organic or inorganic salt." Critically, the disclosed synthesis requires a proton scavenger (1,2,2,6,6-pentamethylpiperidine) during quaternization and trifluoroacetic acid for deprotection — exactly the multi-step, acid-dependent route the '698 specification says it improves upon.
• § 102 relevance: Potentially anticipatory for the generic prodrug concept only — NOT for claims 1–12 as issued. It does not disclose fosnetupitant, the 4-phenyl-pyridine core, netupitant, or the chloride-hydrochloride salt, and it says nothing about a <0.7 %/80-day degradation limit. Its natural role is § 103 (motivation to apply the N-phosphoryloxymethyl promoiety to a tertiary-amine NK-1 antagonist) rather than § 102. Note the '698 specification itself concedes the '856 patent "does not disclose how the N-phosphoryloxymethyl moiety would affect other critical attributes… such as prodrug structure(s), prodrug stability, synthetic cost, and selectivity."

2. US 6,747,026 B2 — Hoffmann-La Roche (mono-N-oxide 4-phenyl-pyridine derivatives)

• Dates: Filed in the 2001–2002 timeframe (Roche 4-phenyl-pyridine series); granted 2004-06-08 (per the series' numbering); cited in the '698 specification.
• Description: Mono-N-oxide derivatives of 4-phenyl-pyridine NK-1 antagonists, reportedly intended to overcome solubility/PK limits of the parent compounds, with no physicochemical or biological data reported (as the '698 specification notes). The '698's own claim proviso — "if a non-pyridine N-oxide is present… the total number of N-oxides… is more than one" — and the statement "the invention excludes all N-oxide forms" are a direct response to this reference.
• § 102 relevance: None for claims 1–12. It is an N-oxide reference; the '698 claims are directed to a phosphonooxymethyl quaternary-ammonium double salt with a stability limit, and the '698 even affirmatively excludes N-oxides. Relevant only as § 103 background and as the reason for the proviso.

B. The admitted 4-phenyl-pyridine / netupitant art

3. US 6,297,375 B1 — "4-phenyl-pyridine derivatives" (Hoffmann-La Roche)

• Dates: Filed 2000-02-22; published/granted 2001-05-02 (per FreePatentsOnline: publication date 10/02/2001); inventors Boes, Branca, Galley, Godel, Hoffmann, Hunkeler, Schnider, Stadler.
• Description: The Roche 4-phenyl-pyridine NK-1 antagonist genus; per the '698 specification, "describes a class of 4-phenyl-pyridine compounds that are NK1 antagonists which are useful for treating CNS disorders," and netupitant is a member of this class. This is the compound-of-record prior art for the parent drug (netupitant).
• § 102 relevance: Potentially anticipatory for the netupitant parent moiety, i.e., it supports the "degradant" limitation (claims 2, 4, 6, 8, 10, 12 — degradants comprising netupitant). It does not disclose the N-phosphonooxymethyl quaternary ammonium salt, the chloride-hydrochloride double salt, or the 80-day stability limit, so it cannot anticipate independent claims 1, 3, 5, 7, 9, 11. Also relevant to § 103 (obvious to make a prodrug of a known tertiary amine).

4. US 6,303,790 B1 — Roche-series citation, listed among the '698 front-page references; I was unable to independently verify its exact subject matter in this session. It appears in the same family/series cluster as the other Roche 4-phenyl-pyridine patents (see items 5–8). Treat as § 103 background, not an anticipator.

5. US 6,479,483 B2 — Roche-series citation; subject matter not independently verified. Background/§ 103 only.

6. US 6,531,597 B2 — Roche-series citation; subject matter not independently verified. Background/§ 103 only.

7. US 6,593,472 B2 — expressly identified in EP 2 722 045 as a Hoffmann-La Roche reference (cited at [0008]/[0033] alongside US 6,297,375, US 6,719,996, US 6,747,026, US 6,806,370). Part of the Roche 4-phenyl-pyridine netupitant series. § 102 relevance: parent-drug/§ 103 background; not an anticipator of the salt claims.

8. US 6,719,996 B2 — Roche-series citation (confirmed as a Hoffmann-La Roche reference in EP 2 722 045 at [0008]). § 102 relevance: parent-drug/§ 103 background; not an anticipator of the salt claims.

9. US 6,806,370 B2 — Roche-series citation (confirmed as Hoffmann-La Roche in EP 2 722 045 at [0033]). § 102 relevance: background/§ 103 only.

10. US 7,211,579 B2 — Listed front-page reference; subject matter not independently verified. On its face a chemistry/pharma reference; § 103 background only.

11. EP 1 103 545 A1 — Cited category "Y" (obviousness) in the ISR of WO 2013/082102. Subject matter not independently verified in this session; per its ISR treatment it is an NK-1/4-phenyl-pyridine-type reference. § 102 relevance: § 103 background; not an anticipator of the issued claims on the information available.

12. WO 02/08232 A1 — Cited category "Y" in the ISR of WO 2013/082102. Subject matter not independently verified. § 103 background only.

13. WO 2006/099968 A1 — Cited category "Y" in the ISR of WO 2013/082102. Subject matter not independently verified. § 103 background only.

14. WO 2009/138393 A1 — Cited category "XY" (novelty + obviousness) in the ISR of WO 2013/082102, i.e., the single most-cited piece of art against the fosnetupitant genus. Subject matter not independently verified in this session. This is the most important non-family reference I could not fully verify and would be the first thing to pull in a full validity study. § 102 relevance: potentially significant against the genus claims of the family, but even on the ISR's own characterization it does not disclose the chloride-hydrochloride double salt or the <0.7 %/80-day limit.

15. JP 2001-527083 A — Japanese national-phase counterpart of the University of Kansas WO 99/33846 (US 5,985,856) family; priority 1997-12-30, University of Kansas, "Water-soluble prodrugs of secondary and tertiary amine-containing drugs and method for producing the same." § 102 relevance: same as US 5,985,856 (item 1) — generic prodrug concept; not an anticipator of the issued claims.

16. JP 2008-534454 A — Japanese reference; subject matter not independently verified. Background/§ 103 only.

C. The Helsinn family references (common priority — generally § 102-excepted)

17. US 8,426,450 B1 — "Substituted 4-phenyl pyridines having anti-emetic effect" (Helsinn)

• Dates: Filed 2012-05-23; granted 2013-04-23; priority 2011-11-29.
• Description: The parent CIP application in the '698's own priority chain; discloses the 4-phenyl-pyridine prodrug genus including GA1 (fosnetupitant) and its salts.
• § 102 relevance: On its face the closest § 102(a)(2)-type reference to claims 1, 3, 5, 7, 9, 11, because it discloses the fosnetupitant molecule and its chloride-hydrochloride salt. BUT it shares the same inventors/assignee and priority date, so it is presumptively excepted under § 102(b)(2)(A)/(C) and, if the '698 claims are entitled to 2011-11-29, it is not § 102(a)(1) art at all (published 2013). Its practical role is § 102 judicial/statutory double patenting and § 103, and indeed the related-family prosecution history shows ODP rejections over family members.

18. WO 2013/082102 A1 — "Substituted 4-phenyl-pyridines for the treatment of NK-1 receptor related diseases" (Helsinn)

• Dates: PCT filed 2012-11-28 (PCT/US2012/066778); published 2013-06-06; priority 2011-11-29 (US 61/564,537) and 2012-05-23 (US 13/478,361). Published as EP 2 785 706 B1 (granted 2016-09-14) and US 2015/0011510 A1.
• Description: The genus application that names GA1–GA8, including GA1 = 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonoxy)methyl)piperazin-1-ium, and its chloride hydrochloride salt. FIG. 1 of WO 2013/082102's US counterpart (US 2015/0011510) is the same "Degradation Behavior Over Time for Various Salts" figure relied on in the '698 (the disodium benchmark plus the better-performing salts, including the chloride hydrochloride).
• § 102 relevance: This is the strongest conceptual § 102 candidate for claim 1, because it discloses both (a) the fosnetupitant molecule/salt and (b) the salt-comparison stability data that underlies the <0.7 %/80-day limitation. It is nonetheless the same family (same inventors, same assignee, common priority), and so is presumptively § 102(b)(2)-excepted. If the '698's stability-limited claims were found not entitled to the 2011/2012 priority (e.g., if the 80-day/<0.7 % data were first added in the 2020 CIP), this reference — published 2013-06-06, more than a year before the 2020 filing — would become the single most dangerous § 102(a)(1) reference. This priority-entitlement question is the pivot of the whole anticipation analysis.

19. US 9,403,772 B2 (Helsinn) — "4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator" (from US 14/360,991); granted 2016-08-02; priority 2011-11-29. Family member disclosing the GA1 compound. § 102 relevance: same family/common-priority analysis as items 17–18; not an independent anticipator.

20. US 2017/050993 A1 (Helsinn) — Published 2017-02-23; the publication of Appl. No. 15/194,984, which issued as US 9,908,907 B2 ("Substituted piperaziniums for the treatment of emesis"); priority 2011-11-29. Family member. § 102 relevance: same common-priority/common-ownership analysis; not an independent anticipator.

21. WO 2011/061622 A1 (Helsinn) — "Compositions for treating centrally mediated nausea and vomiting"; priority 2009-11-18; published 2011-05-26. Relates to netupitant/palonosetron (and the chloride-hydrochloride salt of fosnetupitant) combinations. § 102 relevance: discloses the netupitant/palonosetron combination and its use, not the fosnetupitant chloride-hydrochloride salt with the 80-day stability limit. Relevant as § 103 background on the commercial combination; not an anticipator of claims 1–12.

22. WO 2011/084846 A1 — "Quaternary ammonium salt prodrugs"

• Dates: Priority 2010-01-11 (approx.); published 2011-07-14.
• Description: A WIPO application directed to quaternary ammonium salt prodrugs (the '698 is indexed against it as a family/citing reference). Assignee not verified in this session.
• § 102 relevance: Potentially relevant under § 102(a)(1) as of its 2011-07-14 publication only if the '698 claims are not entitled to the 2011-11-29 priority (it post-dates 2011-11-29). On its face a quaternary-ammonium prodrug genus reference — highly relevant to the promoiety concept, very unlikely to disclose fosnetupitant or the 80-day limit. § 103 background; flag for verification.

23. WO 2013/177224 A1

• Dates: Published 2013-11-28 (approx.).
• Description: Not independently verified in this session. Given the publication date and the '698's citation of it alongside the fosnetupitant family, this is likely a Helsinn solid-form/related application; I could not confirm whether it is the "Crystalline forms of fosnetupitant" or "Crystalline forms of an NK-1 antagonist" family. § 102 relevance: unverified — flag for follow-up, especially because a 2013 crystalline-form disclosure of the chloride-hydrochloride salt would bear directly on claims 7–12 (anhydrate).

2. Non-patent-literature citations (14)

(PubChem's list also includes "Compendium of Organic Synthesis Methods, Vol. I–VI, Wiley-Interscience" and "Handbook of Pharmaceutical Excipients (3rd Ed.), 1999" as cited in the WO counterpart's ISR; these are subsumed in the same § 103 background category.)

3. The most relevant prior art — ranked, with claim mapping

Tier 1 — the only references that come close to an element-by-element § 102 case for claims 1/3/5 (and 7/9/11 if the anhydrate is disclosed):

1. WO 2013/082102 A1 / US 8,426,450 B1 / US 9,403,772 B2 (Helsinn family) — disclose GA1 (fosnetupitant) and its chloride hydrochloride salt, and (in the related US 2015/0011510) present FIG. 1 salt-degradation data — the same figure reproduced in the '698. If claims 1/3/5/7/9/11 are entitled to the 2011-11-29 priority, these are not § 102(a)(1) art (published 2013/2016, after priority) and are § 102(b)(2)-excepted as commonly owned/same-inventor. If those claims are instead held to have a later effective filing date (2020-06-08), WO 2013/082102 becomes a serious § 102(a)(1) anticipator of claims 1, 3, 5, 7, 9, 11 — the priority-entitlement question is therefore the decisive issue. Also the source of ODP exposure (the patent's own family shows § 102-type double-patenting rejections over US 8,623,826, 9,186,357, 9,271,975, 8,951,969).

2. US 5,985,856 A (+ JP 2001-527083 A, + Krise NPL-1/2/3) — the N-phosphoryloxymethyl quaternary-ammonium prodrug genus, including dual-charge/internal-salt forms and pharmaceutically acceptable anions/cations. This is the reference the applicant itself distinguished. It cannot anticipate claims 1–12 (no 4-phenyl-pyridine core, no netupitant, no chloride-hydrochloride salt, no stability limit), but it is the principal § 103 reference and the basis for any obviousness attack on the promoiety.

Tier 2 — parent-compound and combination art (support the "netupitant" degradant limitation, claims 2/4/6/8/10/12; § 103 background for the rest):

1. US 6,297,375 B1 (Hoffmann-La Roche) — the 4-phenyl-pyridine class including netupitant. Directly supports the degradant = netupitant dependent claims, and provides the parent tertiary amine for any § 103 prodrug argument.
2. US 6,593,472 B2 / US 6,719,996 B2 / US 6,747,026 B2 / US 6,806,370 B2 (Hoffmann-La Roche) — the same Roche 4-phenyl-pyridine/N-oxide cluster; parent-drug and § 103 background; the N-oxide reference (US 6,747,026) is the reference the '698's N-oxide proviso and "excludes all N-oxide forms" statement respond to.
3. WO 2011/061622 A1 (Helsinn) — netupitant/palonosetron compositions (published 2011-05-26, pre-priority) — § 103 background on the commercial combination; not an anticipator.

Tier 3 — NK-1 medicinal-chemistry art cited as ISR category "Y"/"XY" (typically § 103, not § 102):

1. WO 2009/138393 A1 (ISR "XY") — the most heavily weighted non-family citation against the fosnetupitant genus; subject matter not verified in this session — priority follow-up item.
2. EP 1 103 545 A1; WO 02/08232 A1; WO 2006/099968 A1 — ISR category "Y"; § 103 background.
3. Giuliani 2011; Hoffmann 2006; Catalani 2011 — 4-phenyl-pyridine/NK-1 medicinal-chemistry papers; § 103 background.

Tier 4 — formulatory/procedural background (no § 102 effect): Remington (1975, 1995), Liberman (1980), Kibbe (1999), Greene/Wuts (1981–2006), Cabrera (2010), Kramer (1998), Gesztesi (2000), the 2013 ISR, and the 2015 JP Office Action.

4. Bottom line on § 102

• No cited reference, taken alone, discloses every element of issued claims 1, 3, 5, 7, 9, 11. The claims are defined by (i) a specific double salt (fosnetupitant chloride hydrochloride) plus (ii) a quantified stability limit (< 0.7 % degradants over 80 days, air/ambient). Only the Helsinn family references supply (i), and only the family's FIG. 1-type data arguably supplies (ii) — and those references are the ones most likely excepted under § 102(b)(2)(A)/(C) or not prior art because of the 2011-11-29 priority.
• The dependents 2, 4, 6, 8, 10, 12 ("degradants comprise netupitant") are the most vulnerable to § 102, because netupitant itself is squarely disclosed by US 6,297,375 and the Roche cluster; the only thing standing between those references and the dependents is the tie to the fosnetupitant salt of the independent claim.
• The genuinely decisive open question is the effective filing date of the stability-limited claims. If they do not carry the 2011-11-29 (or 2012-05-23) priority — because the <0.7 %/80-day characterization was first added in the 2020 CIP — then WO 2013/082102 A1 (published 2013-06-06) is prior art under § 102(a)(1) and is a strong anticipation reference for claims 1, 3, 5 and (depending on anhydrate disclosure) 7, 9, 11, with WO 2011/084846 A1 ("Quaternary ammonium salt prodrugs," published 2011-07-14) also potentially available as of its publication date.

5. Explicit uncertainties I did not resolve

1. WO 2011/084846 A1, WO 2009/138393 A1, WO 2013/177224 A1, EP 1 103 545 A1, WO 02/08232 A1, WO 2006/099968 A1, US 6,303,790, US 6,479,483, US 6,531,597, US 7,211,579, JP 2008-534454 — assignee/subject matter not independently verified in this session; descriptions above are limited to what the citation context supports. A defense-grade analysis must pull each of these.
2. "US 2017/0096442 A1" (Crystalline forms of fosnetupitant) — although not on the '698's front-page citation list, it is the most relevant patent document for claims 7–12 (anhydrate): it discloses Form I fosnetupitant chloride hydrochloride as an anhydrate comprising less than 1.0 wt. % netupitant (Helsinn; priority 2015-10-06; published 2017-04-06). Because it is commonly owned/same-family, it is likely § 102(b)(2)-excepted and is best treated as § 102 double-patenting / § 103 art — but it should be checked. I flag this as an addition beyond the face-of-patent citations.
3. Claim text of claims 3, 5, 9, and 11 as reported by aggregators was truncated (as noted in the earlier-generated sections). The claim-to-reference mapping above should be re-verified against USPTO PatentCenter full text.
4. Priority-entitlement determination (whether the <0.7 %/80-day limitation is supported by US 61/564,537 and/or US 13/478,361) cannot be made from the citation data alone; it requires the provisional and parent specifications.
5. Two apparent citation typos in the source are preserved un-corrected per instruction: (a) J. Pharm. Sci. "vol. 38, No. 9" (should read vol. 88 for the Krise No. 3 paper); (b) Kramer et al., Science "1988" (should read 1998). I did not silently fix either.

I'll verify a few specific points against live sources before drafting the § 103 analysis — particularly the prosecution-history arguments and the non-family references flagged as unverified.

Confirming the identities of the Gland-cited references (Funk, DeGoey, Oslob) and the '698 file history.

Obviousness Analysis of U.S. Patent No. 11,312,698 B2 under 35 U.S.C. § 103

Patent: Fosnetupitant chloride hydrochloride having improved stability · Appl. No. 16/896,135 · Filed 2020‑06‑08 · Granted 2022‑04‑26 · Assignee: Helsinn Healthcare SA
Analysis date: 2026‑04‑26 (per instruction)

How this section builds on the prior work. I do not re‑describe the references catalogued in the Prior Art section; I use them as the reference set and add only what this task required: (a) the identities of the four references that section could not verify, (b) a motivation‑to‑combine analysis, and (c) the claim‑by‑claim obviousness grounds. Two corrections/updates to the prior sections are flagged in § 11.

1. Threshold determinations that control the whole analysis

Two mechanical determinations decide how strong any § 103 case is. They must be resolved before a combination is assembled.

1.1 The AIA governs, and the "prior art" definition is keyed to the effective filing date, not the claimed priority date

Appl. No. 16/896,135 was filed 2020‑06‑08, after 2013‑03‑16. AIA § 102 and AIA § 103 therefore apply even though the patent claims a 2011‑11‑29 priority. AIA § 103 asks whether "the claimed invention as a whole would have been obvious before the effective filing date." The reference‑availability rules of § 102(a)(1)/(a)(2) and the exceptions of § 102(b)(1)/(b)(2) all turn on that same date. Critically, § 102(b)(1)(A)'s grace‑period exception applies only to disclosures made "1 year or less before the effective filing date." A 2013 publication cannot be carried inside a grace period measured from a 2020 date — even if it was authored by the same inventors and commonly owned.

1.2 CIP priority must be claim‑by‑claim, and the '698's claims are a continuation‑in‑part of Ser. No. 13/478,361

The '698 claims benefit to US 61/564,537 (2011‑11‑29) and is a CIP of Ser. No. 13/478,361 (2012‑05‑23). Under § 120 and In re Chu, 66 F.3d 292 (Fed. Cir. 1995), and PowerOasis, Inc. v. T‑Mobile USA, Inc., 522 F.3d 1299 (Fed. Cir. 2008), a CIP claim receives the parent's date only if the parent/provisional provides § 112 support for that claim. New matter added in the CIP gets only the CIP's filing date.

That produces two sharply different worlds:

The single highest‑value issue in any § 103 challenge is Scenario 2. The '698 specification's operative limitation — "less than 0.7% degradants via mass degradation under air and ambient conditions for a period of 80 days" — is a storage‑stability characterization. If that characterization (or the underlying 80‑day dataset) first entered the chain in the 2020 CIP (or in the 2015/2016 crystalline‑forms work), the family's own 2013 publications become § 102(a)(1) art and the case becomes nearly self‑proving. That determination requires the 61/564,537 provisional and the 13/478,361 specification, which I could not retrieve; flagging as unresolved.

2. The claims as actually issued — and a structural finding that reshapes the § 103 case

I confirmed the full issued claim text (DrugPatentWatch, Justia):

• Claim 1 — "Fosnetupitant chloride hydrochloride having the following formula: [structure] wherein the fosnetupitant chloride hydrochloride comprises less than 0.7% degradants via mass degradation under air and ambient conditions for a period of 80 days."
• Claim 2 — claim 1 "wherein the degradants comprise netupitant."
• Claim 3 — "A pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and fosnetupitant chloride hydrochloride having the following formula: [structure]."
• Claim 4 — claim 3 "wherein the degradants in the fosnetupitant chloride hydrochloride comprise netupitant."
• Claim 5 / 6 — injectable composition, same pattern.
• Claim 7 — claim 1 compound "in the form of an anhydrate" plus the same <0.7%/80‑day limitation.
• Claim 8 — the degradant limitation; Claim 9/10 and 11/12 — compositions of the anhydrate.

Structural finding: as printed, claims 3, 5, 9 and 11 recite only the compound's identity plus "one or more pharmaceutically acceptable excipients." They do not recite the <0.7%/80‑day stability limitation at all. The corroboration is internal: claims 4, 6, 10 and 12 refer to "the degradants in the fosnetupitant chloride hydrochloride," yet their parents introduce no degradant antecedent — the drafting defect Gland identified.

Consequences for § 103:

1. The composition claims (3, 5, 9, 11) are bare compound‑plus‑excipient claims. They rise or fall with the compound. If the compound is obvious, a composition comprising it and a pharmaceutically acceptable excipient is obvious. Merck & Co. v. Biocraft Labs., 874 F.2d 804 (Fed. Cir. 1989); KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007).
2. The stability limitation is a product‑by‑property limitation, not a structural difference from the prior‑art molecule. That engages inherency and result‑effective‑variable doctrine (§ 5.2 below).
3. No method claims exist in the '698. The specification's touted advance — a "one‑step, acid‑free synthesis" replacing the prior art's "proton scavengers" and "strong acid" deprotection — is not claimed. Non‑claimed advantages cannot supply patentability to a product claim. The claimed invention "as a whole" is the salt.

Verification caveat: the aggregator renderings truncate the formula images. My conclusion that claims 3/5/9/11 omit the stability limitation rests on two independent sources returning the same text and on the antecedent‑basis defect in the dependents. It should be confirmed against the printed patent / PatentCenter certified text.

3. Person of ordinary skill in the art (POSA)

A POSA at the 2011–2012 effective date (and equally at 2020) would be a medicinal chemist or pharmaceutical scientist with a Ph.D. (or M.S. plus several years) in organic/medicinal chemistry or pharmaceutics, with practical experience in (i) GPCR/NK₁ antagonist medicinal chemistry, (ii) prodrug design for tertiary amines, (iii) salt and polymorph screening, and (iv) ICH‑style solid‑state and solution stability testing. The field is unpredictable in vivo but highly predictable in the salt‑screening and prodrug‑activation mechanics that the claims turn on. That predictability is decisive under KSR.

4. Reference‑availability triage (updating, not repeating, the Prior Art section)

The prior section catalogued 23 patent documents and 16 NPL items. For § 103 the relevant classification is:

Tier A — third‑party art available under either scenario, and squarely on point

Tier B — Helsinn‑family art: out as § 103 art in Scenario 1; full art in Scenario 2

WO 2013/082102 A1; US 8,426,450 B1; US 9,403,772 B2; US 2017/0050993 A1 (issued as US 9,908,907 B2); US 2017/0096442 A1 / WO 2017/060338 A1. In Scenario 2 these supply (a) the exact compound, (b) the exact chloride hydrochloride salt, and (c) FIG. 1 salt‑degradation data with the disodium salt as benchmark — the same figure reproduced in the '698.

Tier C — secondary/§ 103‑support only: the remaining Roche cluster (US 6,303,790 (Hilpert et al.), US 6,531,597 (Hoffmann‑Emery et al.), US 6,593,472 (Hoffmann et al.), US 6,719,996 (Kuentz et al.), US 6,747,026 (Hoffmann et al., N‑oxides), US 6,806,370 (Hoffmann et al.)); EP 1 103 545 A1; WO 02/08232 A1; WO 2006/099968 A1; WO 2011/061622 A1 (netupitant/palonosetron combination, pub. 2011‑05‑26); Giuliani 2011; Hoffmann 2006; Catalani 2011; and the formulation texts (Remington 1975/1995; Liberman 1980; Kibbe 1999; Greene/Wuts).

Tier D — verified only to the level of Gland's pleading: DeGoey and Oslob. Gland's Twentieth Counterclaim pleads § 103 "in light of at least the following prior art: WO '846; Bös; Funk; DeGoey; Krise I; and Oslob." I could not verify DeGoey's or Oslob's subject matter this session. Given their position in a six‑reference combination aimed at a phosphate‑prodrug quaternary ammonium salt, they most plausibly supply NK₁/4‑phenylpyridine chemistry and/or phosphate‑prodrug chemistry respectively — but I will not characterize them further, and they should be pulled from the Second Notice Letter before being relied upon.

Note on "WO '846": the most likely referent is WO 2011/084846 (Alkermes), which is the only "*846" on the '698's own face and the only one that is a quaternary‑ammonium‑prodrug reference. Gland's shorthand should be confirmed against the notice letter; if it instead denotes a different document, that reference must be substituted into the grounds below.

5. The motivation‑to‑combine ledger (KSR rationales)

A § 103 combination requires an articulated reason. Here, at least six independent rationales converge:

1. A recognized problem with a known solution. Netupitant is a poorly water‑soluble, orally dosed NK₁ antagonist; the art (including the '698's own background and WO 2011/061622) is directed to CINV regimens and to IV administration. Stella's class exists for exactly one purpose: converting poorly soluble tertiary‑amine drugs into water‑soluble phosphate prodrugs. Netupitant's N‑methylpiperazine is a tertiary amine — a single, obvious, structurally indicated site.
2. Reasonable expectation of success. Krise I–III taught that N‑phosphonooxymethyl quaternary ammonium prodrugs (a) markedly improve aqueous solubility and (b) are cleaved in vivo to the parent drug, and demonstrated conversion in rat and dog. The '698's own data (rat/dog IV conversion to netupitant; bioequivalence to oral netupitant in dog) are confirmation of the expected result, not an unexpected one.
3. Known, finite, predictable technique; predictable variations. The route is a two‑step quaternization/deprotection with a named commercial reagent (chloromethyl di‑tert‑butyl phosphate) — Krise I. KSR ("a finite number of identified, predictable solutions"); Medichem v. Rolabo, 437 F.3d 1157 (Fed. Cir. 2006).
4. Routine salt selection. Pfizer, Inc. v. Apotex, Inc., 480 F.3d 1348 (Fed. Cir. 2007) (salt selection is a routine, predictable exercise; amlodipine besylate obvious). WO 2011/084846 expressly frames counterion choice as a property‑modulating variable ("further modulated by the choice of counterion X⁻"). WO 2009/138393 lists hydrochloric acid and quaternary ammonium salts as ordinary options. Bös' US 6,473,483 already makes the netupitant·2HCl salt of the very piperazine core.
5. Inherence of the claimed double salt in the known synthesis. In Krise I the quaternizing reagent is a chloride (chloromethyl di‑tert‑butyl phosphate), so the quaternary ammonium counter‑ion of the immediate product is chloride; deprotection with strong acid (TFA) then yields the phosphate monoester in its acid form — i.e., the conjugate acid. The '698's own specification admits the prior art used "strong acid to deprotect the phosphate group." The claimed "chloride hydrochloride" is thus the direct, predictable product of the known route — the same molecular entity reached by the prior‑art process.
6. Known problem with the prior art's preferred form supplies the direction. The '698 specification states the prior art preferred dibasic salts of the phosphooxymethyl substituent and that those salts "are unstable and reform the underlying drug during storage." That is an admission that (a) the salt/stability question was live in the art and (b) the counter‑ion/protonation state governing storage reversion was a result‑effective variable the artisan had reason to optimize.

6. Grounds of rejection

GROUND 1 — Claims 3, 5, 9, 11 (compound‑identity composition claims)

Primary: Bös, US 6,297,375 B1 (netupitant genus/species; the N‑methylpiperazine tertiary amine) — alone or with US 6,473,483 B2 (netupitant·2HCl).
Secondary: Stella, US 5,985,856 A (+ JP 2001‑527083 A); Krise I; and WO 2011/084846 ("quaternary ammonium salt prodrugs"; counterion as a property variable).

Rejection: It would have been obvious to (i) select the known species netupitant from Bös, (ii) convert its N‑methylpiperazine to the known phosphonooxymethyl quaternary ammonium prodrug using the known chloromethyl di‑tert‑butyl phosphate reagent and acid deprotection of Krise I/'856, and (iii) formulate the resulting chloride hydrochloride with one or more pharmaceutically acceptable excipients — the latter step being routine and requiring no inventive input (Merck v. Biocraft). Claims 3/5/9/11 recite no stability limitation, so no secondary‑consideration evidence directed at the salt's storage stability is commensurate with their scope.

GROUND 2 — Claims 1 and 2 (the double salt + the <0.7%/80‑day limitation)

Combination: Bös (US 6,297,375) + Stella ('856/Krise I) + WO 2011/084846, and — in Scenario 2 — WO 2013/082102 / US 8,426,450 / US 2017/0050993.

Two independent theories dispose of the stability limitation:

(a) Product‑by‑property / inherency. A claimed property of a chemical compound is not a separate patentable element: the prior art compound inherently possesses all of its properties. In re Oelrich, 579 F.2d 86, 91 (CCPA 1978); In re Best, 562 F.2d 1252, 1254‑55 (CCPA 1977) (where the claimed and prior‑art products are identical or substantially identical, the burden shifts to the applicant to show the prior‑art product does not possess the claimed characteristic). Because claim 1 does not define any structural difference from fosnetupitant chloride hydrochloride, and because the same molecular entity is obtained by the prior‑art quaternization/deprotection route, the PTO or a challenger may put the burden on Helsinn to prove the prior‑art product degrades more than 0.7 % in 80 days. The specification's own FIG. 1 — a salt screen of the same parent compound in which "a few salts … manifested more desirous results than the disodium salt" — shows the value was found by routine screening.

(b) Routine optimization of a result‑effective variable. Purity/stability is a classic result‑effective variable; obtaining a compound in a more stable protonation/counter‑ion state by routine experimentation is obvious absent evidence of unexpected results. In re Aller, 220 F.2d 454, 456 (CCPA 1955) (optimum values of known variables); cf. In re Boesch, 617 F.2d 272 (CCPA 1980). The '698 offers no disclosed measuring protocol for "mass degradation under air and ambient conditions" and no comparative dataset beyond FIG. 1, so there is nothing on which a non‑obviousness‑of‑degree finding could rest.

In Scenario 2, this ground collapses further into § 102: WO 2013/082102 / US 8,426,450 disclose the fosnetupitant chloride hydrochloride salt and the FIG. 1 degradation‑over‑time data. That is element‑for‑element subject matter, and no combination is needed.

GROUND 3 — Claims 7 and 8 (the anhydrate)

Combination: Ground 2 + the general art on anhydrous vs. hydrated salt forms, + (Scenario 2) US 2017/0096442 A1 / WO 2017/060338 A1 (Crystalline Forms of Fosnetupitant, now verified).

Rejection: Claim 7 adds only "in the form of an anhydrate." Desolvation/dehydration of a salt is a routine unit operation; a claim to an anhydrous form of a known salt, absent unexpected properties, is obvious. In re Rosuvastatin Calcium Patent Litig., 703 F.3d 511 (Fed. Cir. 2012); SmithKline Beecham Corp. v. Apotex Corp., 439 F.3d 1312 (Fed. Cir. 2006) (paroxetine hydrochloride anhydrate). The crystalline‑forms application supplies the explicit motivation in its own words: "Anhydrous forms are often desirable because they can be consistently made without concern for variation in weight or composition due to varying solvent or water content," and its examples dry the isolated chloride hydrochloride under vacuum at 40 °C. In Scenario 1, that reference is commonly owned and § 102(b)(2)(C)‑excepted from § 103; the ground then rests on the routine‑optimization rationale plus whatever the '856/Krise isolation procedures inherently yield.

GROUND 4 — Claims 2, 4, 6, 8, 10, 12 ("the degradants comprise netupitant")

Rejection: These dependents add only the identity of the degradation product. That identity is taught by the prodrug art itself: Krise I–III establish that N‑phosphonooxymethyl prodrugs revert to the parent tertiary amine by enzymatic/chemical cleavage of the phosphonooxymethyl group. The '698 specification confirms it in terms: the salt "is tremendously resistant to decoupling of the oxo‑phosphonomethyl, and reversion of the active moiety to its parent state." The parent is netupitant (Bös, US 6,297,375). A dependent claim adding a known, inherent consequence of the known prodrug architecture adds nothing patentable.

GROUND 5 (Scenario 2 alternative) — the family‑art ground

WO 2013/082102 A1 (or US 8,426,450 B1 / US 9,403,772 B2) discloses GA1 and its chloride hydrochloride salt, and the same FIG. 1 salt‑degradation data, and US 2017/0096442 A1 discloses Form I fosnetupitant chloride hydrochloride characterized as containing less than 1.0 or 0.5 wt. % netupitant (the "parent molecule"). A single reference or a two‑reference combination therefore reaches every element of claims 1–12 — under § 102 where the compound and limit are identical, and under § 103 (motivation: improve purity/stability for an injectable product; predictable technique) with the remaining gap, if any, filled by the salt‑screening and anhydrate art. KSR; Pfizer v. Apotex.

7. Anticipated patent‑owner arguments and why they fail

8. Overlapping doctrines that should be run with the § 103 case

1. Obviousness‑type double patenting (ODP). The prior art section records § 102‑type double‑patenting rejections in this very family over US 8,623,826, US 9,186,357, US 9,271,975 and US 8,951,969. The '698's claims — particularly claims 3/5/9/11, which add only "excipients" to a compound claimed in the family — are prime ODP candidates against US 8,426,450 / US 9,403,772 / US 12,071,421. ODP is not subject to § 315(e)(2) estoppel and does not depend on new art.
2. § 112 indefiniteness / non‑enablement of the stability limitation. "Less than 0.7% degradants via mass degradation under air and ambient conditions" specifies no temperature, humidity, container, sample form, or analytical method. This is Gland's pleading (ECF 25 ¶ 127) and is the least‑resolved, most art‑independent theory. If indefinite, the limitation cannot be relied on to distinguish art and the claim cannot be infringed.
3. § 102(a)(1) in Scenario 2 (see Ground 5), which is strictly stronger than § 103 and should be pleaded in the alternative.

9. Claim‑by‑claim conclusion

Bottom line: claims 3, 5, 9 and 11 are the most exposed — they contain no stability limitation at all, and a composition claim to an obvious compound plus a carrier is obvious under Merck v. Biocraft and KSR. Claims 1 and 7 turn on a single, weakly supported product‑by‑property limitation that is vulnerable to inherency doctrine (In re Best, In re Oelrich) and to routine‑optimization doctrine (In re Aller, Pfizer v. Apotex) — and, if the CIP's effective filing date governs, to outright § 102 anticipation by Helsinn's own 2013 publications, which fall outside the § 102(b)(1) grace period because they precede the 2020 effective filing date by more than a year.

10. Open items / verification list

1. Effective‑filing‑date determination — pull US 61/564,537 and 13/478,361 and determine whether the "<0.7 %/80 days" limitation and its supporting data were present. This is the pivot of the whole § 103 analysis.
2. Identify "DeGoey" and "Oslob" in Gland's Second Notice Letter and verify their subject matter (I could not).
3. Confirm "WO '846" = WO 2011/084846 and not another '*846' document.
4. Confirm the printed text of claims 3/5/9/11 (whether the stability limitation appears inside the formula images).
5. Verify WO 2013/177224 A1, US 6,303,790, US 6,479,483, US 6,531,597, US 7,211,579's claim scope, EP 1 103 545 A1, WO 02/08232 A1, WO 2006/099968 A1, JP 2008‑534454 — still unverified to reference‑specific detail.
6. Locate the '698 file wrapper (App. 16/896,135; Examiner Douglas M. Willis) to see which reference(s) were applied, whether the 0.7 % limitation was added by amendment, and whether a terminal disclaimer was filed.

Source typos preserved un‑corrected (per operating rules): Kramer et al., Science "1988" (should read 1998); Krise No. 3, J. Pharm. Sci. "vol. 38, No. 9" (should read vol. 88).

11. Updates and a correction to the previously generated sections

• Update (Prior Art § 5, item 1): WO 2011/084846 A1 is now verified — "Quaternary ammonium salt prodrugs," Alkermes, Inc., inventors Almarsson, Blumberg, Remenar; priority US provisionals 61/293,124/153/163/171 filed 2010‑01‑07; filed 2010‑12‑23; published 2011‑07‑14; US counterpart US 2011/0178068 A1 (2011‑07‑21) issuing as US 9,670,200 B2 (2017‑06‑06). This matters because its publication date falls before the earliest claimed priority date, making it § 102(a)(1) art even in Scenario 1.
• Update (Prior Art § 5, item 14): WO 2009/138393 A1 is now verified — 5‑[5‑[2‑(3,5‑bis(trifluoromethyl)phenyl)‑2‑methylpropanoylmethylamino]‑4‑(4‑fluoro‑2‑methylphenyl)]‑2‑pyridinyl‑2‑alkyl‑prolinamides as NK₁ antagonists; applicant Glaxo Wellcome Manufacturing Pte Ltd / NeRRe Therapeutics; priority GB 0808747 (2008‑05‑14); published 2009‑11‑19 as EP 2 300 452 A1. It expressly collects "hydrochloric" acid salts and "quaternary ammonium salts and internally formed salts," and cites WO 02/16324 (Roche) for 4‑phenylpyridine NK₁ antagonists.
• Update (Prior Art § 5, item 10): US 7,211,579 B2 ("Funk") is now confirmed as "NK‑1 receptor antagonists," Hoffmann‑La Roche, inventors Funk, Hoffmann and Koblet, granted 2007‑05‑01 from App. 11/376,042 — consistent with Gland's citation of "Funk."
• Correction to the Patent summary: the Litigation section is correct and the Patent summary is wrong — no AIA trial has ever targeted US 11,312,698. That correction was already made in the PTAB section; I restate it here only because the patent‑summary error ("IPR2025‑00948 may target the '698 patent") would otherwise distort the § 103 posture. Because no IPR exists on this patent, § 315(e)(2) estoppel attaches to no one, and every ground above remains available in any forum.

This is a technical/analytical assessment grounded in the cited public documents, not legal advice; validity determinations are ultimately for the courts or the Board.